HIV Drug Resistance

HIV drug resistance (HIVDR) is the ability of HIV to mutate and reproduce in the presence of antiretroviral (ARV) drugs. The consequences of drug resistance include treatment failure; the transmission of drug resistant HIV; as well as increased direct and indirect costs, for patients and health systems, due to more expensive, complex and toxic second- and third-line ARV regimens.

PAHO/WHO recommend a public health approach to HIVDR based on a comprehensive package of tools that should be implemented in all countries scaling-up and maintaining populations on antiretroviral therapy (ART). The WHO Global Action Plan on HIVDR (2017-2021) provides countries a framework for action with five strategic objectives: 1) prevention and response; 2) monitoring and surveillance; 3) research and innovation; 4) laboratory capacity; and 5) governance and enabling mechanisms.

The WHO strategy includes:

The WHO/HIVResNet laboratory strategy supports the implementation of HIVDR surveys by providing accurate and timely genotyping that meet WHO specifications.


External parties material